13 research outputs found

    Arctic sea-ice decline weakens the Atlantic Meridional Overturning Circulation

    No full text
    The ongoing decline of Arctic sea ice exposes the ocean to anomalous surface heat and freshwater fluxes, resulting in positive buoyancy anomalies that can affect ocean circulation. In this study, we use an optimal flux perturbation framework and comprehensive climate model simulations to estimate the sensitivity of the Atlantic Meridional Overturning Circulation (AMOC) to such buoyancy forcing over the Arctic and globally, and more generally to sea-ice decline. It is found that on decadal timescales, flux anomalies over the subpolar North Atlantic have the largest impact on the AMOC, while on multi-decadal timescales (longer than 20 years), flux anomalies in the Arctic become more important. These positive buoyancy anomalies spread to the North Atlantic, weakening the AMOC and its poleward heat transport. Therefore, the Arctic sea-ice decline may explain the suggested slow-down of the AMOC and the ‘Warming Hole’ persisting in the subpolar North Atlantic

    Cost-Effectiveness Of Increasing Influenza Vaccination Coverage In Adults With Type 2 Diabetes In Turkey

    No full text
    Objective In Turkey, the prevalence of diabetes is high but the influenza vaccination coverage rate (VCR) is low (9.1% in 2014), despite vaccination being recommended and reimbursed. This study evaluated the cost-effectiveness of increasing the influenza VCR of adults with type 2 diabetes in Turkey to 20%. Methods A decision-analytic model was adapted to Turkey using data derived from published sources. Direct medical costs and indirect costs due to productivity loss were included in the societal perspective. The time horizon was set at 1 year to reflect the seasonality of influenza. Results Increasing the VCR for adults with type 2 diabetes to 20% is predicted to avert an additional 19,777 influenza cases, 2376 hospitalizations, and 236 deaths. Associated influenza costs avoided were estimated at more than 8.3 million Turkish Lira (TRY), while the cost of vaccination would be more than TRY 8.4 million. The incremental cost-effectiveness ratio was estimated at TRY 64/quality-adjusted life years, which is below the per capita gross domestic product of TRY 21,511 and therefore very cost-effective according to World Health Organization guidelines. Factors most influencing the incremental cost-effectiveness ratio were the excess hospitalization rate, inpatient cost, vaccine effectiveness against hospitalization, and influenza attack rate. Increasing the VCR to >20% was also estimated to be very cost-effective. Conclusions Increasing the VCR for adults with type 2 diabetes in Turkey to ≥20% would be very cost-effective.PubMedWoSScopu
    corecore